Generic
Takeda’s Vyvanse faces generic competition after 16 years of ADHD dominance
Anika Sharma
Vyvanse, a blockbuster drug for attention-deficit/hyperactivity disorder (ADHD) and binge-eating disorder, has been the top choice for many patients and ...
Legal Battle Unfolds as Endo’s Par Pharmaceuticals Defends Exclusive Rights to Chantix Amid Generic Rivalry
SG Tylor
Following the recall of Pfizer’s smoking cessation drug Chantix in 2021, Endo’s subsidiary Par Pharmaceuticals has stood as the sole ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
SG Tylor
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
AbbVie Raises Profit Expectations Despite Q2 Decrease in Humira and Imbruvica Sales
SG Tylor
AbbVie executives express satisfaction with the introduction of Humira biosimilars in the US, despite facing significant revenue declines for both ...
VPAS negotiations are prohibited by the UK High Court from taking place
SG Tylor
The British Generic Manufacturers Association (BGMA) has been denied a seat at the negotiation table for the new Voluntary Scheme ...
